KalVista Pharmaceuticals (KALV) Stock Forecast, Price Target & Predictions
KALV Stock Forecast
KalVista Pharmaceuticals stock forecast is as follows: an average price target of $26.00 (represents a 123.56% upside from KALV’s last price of $11.63) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
KALV Price Target
The average price target for KalVista Pharmaceuticals (KALV) is $26.00 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $38.00 to $20.00. This represents a potential 123.56% upside from KALV's last price of $11.63.
KALV Analyst Ratings
According to 4 Wall Street analysts, KalVista Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for KALV stock is 0 'Strong Buy' (0.00%), 4 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
KalVista Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 06, 2024 | Andrew Fein | H.C. Wainwright | $20.00 | $12.87 | 55.40% | 71.97% |
| Sep 06, 2024 | Joseph Schwartz | Leerink Partners | $20.00 | $12.87 | 55.40% | 71.97% |
| Jul 08, 2022 | - | Needham | $38.00 | $10.98 | 246.08% | 226.74% |
The latest KalVista Pharmaceuticals stock forecast, released on Sep 06, 2024 by Andrew Fein from H.C. Wainwright, set a price target of $20.00, which represents a 55.40% increase from the stock price at the time of the forecast ($12.87), and a 71.97% increase from KALV last price ($11.63).
KalVista Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 2 | 2 |
| Avg Price Target | - | $20.00 | $20.00 |
| Last Closing Price | $11.63 | $11.63 | $11.63 |
| Upside/Downside | -100.00% | 71.97% | 71.97% |
In the current month, the average price target of KalVista Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to KalVista Pharmaceuticals's last price of $11.63. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 06, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Sep 06, 2024 | Leerink Partners | Outperform | Outperform | Hold |
| Feb 03, 2023 | SVB Leerink | Outperform | Outperform | Hold |
| Jul 08, 2022 | SVB Leerink | Outperform | Outperform | Hold |
| Jul 08, 2022 | Needham | Buy | Buy | Hold |
KalVista Pharmaceuticals's last stock rating was published by H.C. Wainwright on Sep 06, 2024. The company gave KALV a "Buy" rating, the same as its previous rate.
KalVista Pharmaceuticals Financial Forecast
KalVista Pharmaceuticals Revenue Forecast
| May 26 | Jan 26 | Oct 25 | Jul 25 | May 25 | Jan 25 | Oct 24 | Jul 24 | May 24 | May 21 | Jan 21 | Oct 20 | Jul 20 | May 20 | Jan 20 | Oct 19 | Jul 19 | May 19 | Jan 19 | May 18 | Oct 17 | May 16 | May 15 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $1.58M | $3.92M | $3.37M | - | $3.89M | - | $1.13M | - | - |
| Avg Forecast | $28.34M | $17.00M | $11.34M | - | $4.20M | $1.97M | $518.00K | - | $4.46M | $420.00K | $1.20M | $625.00K | $1.50M | $1.90M | $10.08M | $3.27M | $3.22M | $4.03M | $4.25M | $618.16K | $115.69K | $7.40K | $266.76K |
| High Forecast | $28.34M | $17.00M | $11.34M | - | $4.20M | $1.97M | $518.00K | - | $4.46M | $504.00K | $1.20M | $625.00K | $1.50M | $1.90M | $10.08M | $3.27M | $3.22M | $4.03M | $4.25M | $741.79K | $138.82K | $8.88K | $320.12K |
| Low Forecast | $28.34M | $17.00M | $11.34M | - | $4.20M | $1.97M | $518.00K | - | $4.46M | $336.00K | $1.20M | $625.00K | $1.50M | $1.90M | $10.08M | $3.27M | $3.22M | $4.03M | $4.25M | $494.53K | $92.55K | $5.92K | $213.41K |
| # Analysts | 1 | 1 | 1 | - | 1 | 2 | 1 | - | 1 | 14 | 10 | 10 | 7 | 12 | 7 | 6 | 3 | 3 | 6 | 9 | 17 | 8 | 19 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.16% | 1.20% | 1.05% | - | 0.91% | - | 9.74% | - | - |
KalVista Pharmaceuticals's average Quarter revenue forecast for May 20 based on 12 analysts is $1.90M, with a low forecast of $1.90M, and a high forecast of $1.90M. KALV's average Quarter revenue forecast represents a 20.21% increase compared to the company's last Quarter revenue of $1.58M (Jan 20).
KalVista Pharmaceuticals EBITDA Forecast
| May 26 | Jan 26 | Oct 25 | Jul 25 | May 25 | Jan 25 | Oct 24 | Jul 24 | May 24 | May 21 | Jan 21 | Oct 20 | Jul 20 | May 20 | Jan 20 | Oct 19 | Jul 19 | May 19 | Jan 19 | May 18 | Oct 17 | May 16 | May 15 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | - | 1 | 2 | 1 | - | 1 | 14 | 10 | 10 | 7 | 12 | 7 | 6 | 3 | 3 | 6 | 9 | 17 | 8 | 19 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | $-12.82M | $-12.62M | $-14.75M | - | $-12.58M | $-9.59M | $-8.85M | - | $-6.80M | - | $-5.97M | - | - |
| Avg Forecast | $5.67M | $3.40M | $2.27M | - | $839.31K | $394.60K | $103.60K | - | $892.05K | $-13.87M | $240.00K | $125.00K | $300.00K | $-9.91M | $2.02M | $653.23K | $644.20K | $-5.16M | $850.60K | $-8.25M | $-5.56M | $-4.21M | $-164.52M |
| High Forecast | $5.67M | $3.40M | $2.27M | - | $839.31K | $394.60K | $103.60K | - | $892.05K | $-11.10M | $240.00K | $125.00K | $300.00K | $-7.93M | $2.02M | $653.23K | $644.20K | $-4.13M | $850.60K | $-6.60M | $-4.45M | $-3.37M | $-131.61M |
| Low Forecast | $5.67M | $3.40M | $2.27M | - | $839.31K | $394.60K | $103.60K | - | $892.05K | $-16.65M | $240.00K | $125.00K | $300.00K | $-11.90M | $2.02M | $653.23K | $644.20K | $-6.20M | $850.60K | $-9.91M | $-6.67M | $-5.05M | $-197.42M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | -53.43% | -100.99% | -49.18% | - | -6.24% | -14.68% | -13.74% | - | -8.00% | - | 1.07% | - | - |
undefined analysts predict KALV's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than KalVista Pharmaceuticals's previous annual EBITDA (undefined) of $NaN.
KalVista Pharmaceuticals Net Income Forecast
| May 26 | Jan 26 | Oct 25 | Jul 25 | May 25 | Jan 25 | Oct 24 | Jul 24 | May 24 | May 21 | Jan 21 | Oct 20 | Jul 20 | May 20 | Jan 20 | Oct 19 | Jul 19 | May 19 | Jan 19 | May 18 | Oct 17 | May 16 | May 15 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | - | 1 | 2 | 1 | - | 1 | 14 | 10 | 10 | 7 | 12 | 7 | 6 | 3 | 3 | 6 | 9 | 17 | 8 | 19 |
| Net Income | - | - | - | - | - | - | - | - | - | - | $-10.05M | $-10.43M | $-10.81M | - | $-9.29M | $-5.90M | $-7.34M | - | $-3.96M | - | $-4.99M | - | - |
| Avg Forecast | $-24.97M | $-32.83M | $-34.67M | $-40.69M | $-38.90M | $-42.01M | $-42.86M | $-42.30M | $-32.95M | $-10.87M | $-27.54M | $-31.04M | $-27.66M | $-10.22M | $-12.09M | $-25.43M | $-28.51M | $-5.30M | $-20.71M | $-8.33M | $-5.60M | $-4.29M | $-197.56M |
| High Forecast | $-24.97M | $-32.83M | $-34.67M | $-40.69M | $-38.90M | $-31.39M | $-42.40M | $-42.30M | $-32.95M | $-8.70M | $-27.54M | $-31.04M | $-27.66M | $-8.18M | $-12.09M | $-25.43M | $-28.51M | $-4.24M | $-20.71M | $-6.67M | $-4.48M | $-3.43M | $-158.05M |
| Low Forecast | $-24.97M | $-32.83M | $-34.67M | $-40.69M | $-38.90M | $-49.39M | $-43.80M | $-42.30M | $-32.95M | $-13.05M | $-27.54M | $-31.04M | $-27.66M | $-12.26M | $-12.09M | $-25.43M | $-28.51M | $-6.36M | $-20.71M | $-10.00M | $-6.72M | $-5.14M | $-237.07M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 0.36% | 0.34% | 0.39% | - | 0.77% | 0.23% | 0.26% | - | 0.19% | - | 0.89% | - | - |
KalVista Pharmaceuticals's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. KALV's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
KalVista Pharmaceuticals SG&A Forecast
| May 26 | Jan 26 | Oct 25 | Jul 25 | May 25 | Jan 25 | Oct 24 | Jul 24 | May 24 | May 21 | Jan 21 | Oct 20 | Jul 20 | May 20 | Jan 20 | Oct 19 | Jul 19 | May 19 | Jan 19 | May 18 | Oct 17 | May 16 | May 15 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | - | 1 | 2 | 1 | - | 1 | 14 | 10 | 10 | 7 | 12 | 7 | 6 | 3 | 3 | 6 | 9 | 17 | 8 | 19 |
| SG&A | - | - | - | - | - | - | - | - | - | - | $3.56M | $3.63M | $3.28M | - | $3.07M | $3.42M | $3.25M | - | $2.90M | - | $2.70M | - | - |
| Avg Forecast | $30.26M | $18.15M | $12.10M | - | $4.48M | $2.11M | $552.99K | - | $4.76M | $448.37K | $1.28M | $667.22K | $1.60M | $2.02M | $10.76M | $3.49M | $3.44M | $3.89M | $4.54M | $659.92K | $123.50K | $7.90K | $284.78K |
| High Forecast | $30.26M | $18.15M | $12.10M | - | $4.48M | $2.11M | $552.99K | - | $4.76M | $538.04K | $1.28M | $667.22K | $1.60M | $2.02M | $10.76M | $3.49M | $3.44M | $4.66M | $4.54M | $791.90K | $148.20K | $9.48K | $341.74K |
| Low Forecast | $30.26M | $18.15M | $12.10M | - | $4.48M | $2.11M | $552.99K | - | $4.76M | $358.70K | $1.28M | $667.22K | $1.60M | $2.02M | $10.76M | $3.49M | $3.44M | $3.11M | $4.54M | $527.93K | $98.80K | $6.32K | $227.82K |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 2.78% | 5.44% | 2.05% | - | 0.29% | 0.98% | 0.94% | - | 0.64% | - | 21.89% | - | - |
KalVista Pharmaceuticals's average Quarter SG&A projection for May 21 is $448.37K, based on 14 Wall Street analysts, with a range of $358.70K to $538.04K. The forecast indicates a -87.41% fall compared to KALV last annual SG&A of $3.56M (Jan 21).
KalVista Pharmaceuticals EPS Forecast
| May 26 | Jan 26 | Oct 25 | Jul 25 | May 25 | Jan 25 | Oct 24 | Jul 24 | May 24 | May 21 | Jan 21 | Oct 20 | Jul 20 | May 20 | Jan 20 | Oct 19 | Jul 19 | May 19 | Jan 19 | May 18 | Oct 17 | May 16 | May 15 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | - | 1 | 2 | 1 | - | 1 | 14 | 10 | 10 | 7 | 12 | 7 | 6 | 3 | 3 | 6 | 9 | 17 | 8 | 19 |
| EPS | - | - | - | - | - | - | - | - | - | - | $-0.39 | $-0.44 | $-0.36 | - | $-0.30 | $-0.11 | $-0.32 | - | $-0.06 | - | $-0.40 | - | - |
| Avg Forecast | $-0.54 | $-0.71 | $-0.75 | $-0.88 | $-0.84 | $-0.91 | $-0.93 | $-0.92 | $-0.71 | $-0.53 | $-0.60 | $-0.67 | $-0.60 | $-0.65 | $-0.26 | $-0.55 | $-0.62 | $-0.35 | $-0.45 | $-0.21 | $-0.67 | $-1.68 | $-88.79 |
| High Forecast | $-0.54 | $-0.71 | $-0.75 | $-0.88 | $-0.84 | $-0.68 | $-0.92 | $-0.92 | $-0.71 | $-0.53 | $-0.60 | $-0.67 | $-0.60 | $-0.65 | $-0.26 | $-0.55 | $-0.62 | $-0.35 | $-0.45 | $-0.17 | $-0.54 | $-1.34 | $-71.04 |
| Low Forecast | $-0.54 | $-0.71 | $-0.75 | $-0.88 | $-0.84 | $-1.07 | $-0.95 | $-0.92 | $-0.71 | $-0.53 | $-0.60 | $-0.67 | $-0.60 | $-0.65 | $-0.26 | $-0.55 | $-0.62 | $-0.35 | $-0.45 | $-0.25 | $-0.80 | $-2.02 | $-106.55 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 0.65% | 0.66% | 0.60% | - | 1.15% | 0.20% | 0.52% | - | 0.13% | - | 0.60% | - | - |
According to undefined Wall Street analysts, KalVista Pharmaceuticals's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to KALV previous annual EPS of $NaN (undefined).
KalVista Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| KRON | Kronos Bio | $0.95 | $7.63 | 703.16% | Buy |
| GOSS | Gossamer Bio | $0.89 | $3.75 | 321.35% | Buy |
| LRMR | Larimar Therapeutics | $7.57 | $20.33 | 168.56% | Buy |
| IMCR | Immunocore | $31.17 | $70.75 | 126.98% | Buy |
| KALV | KalVista Pharmaceuticals | $11.63 | $26.00 | 123.56% | Buy |
| REPL | Replimune Group | $12.02 | $24.20 | 101.33% | Buy |
| CGEM | Cullinan Oncology | $15.92 | $31.50 | 97.86% | Buy |
| LYRA | Lyra Therapeutics | $0.26 | $0.50 | 92.31% | Hold |
| SNDX | Syndax Pharmaceuticals | $18.94 | $36.11 | 90.65% | Buy |
| VRDN | Viridian Therapeutics | $22.84 | $37.83 | 65.63% | Buy |
| MRSN | Mersana Therapeutics | $1.84 | $3.00 | 63.04% | Buy |
| CYTK | Cytokinetics | $51.48 | $83.23 | 61.67% | Buy |
| COGT | Cogent Biosciences | $11.87 | $18.83 | 58.64% | Buy |
| DYN | Dyne Therapeutics | $28.78 | $43.88 | 52.47% | Buy |
| KURA | Kura Oncology | $17.81 | $26.00 | 45.99% | Buy |
| MIRM | Mirum Pharmaceuticals | $40.45 | $54.50 | 34.73% | Buy |
| EWTX | Edgewise Therapeutics | $34.48 | $45.00 | 30.51% | Buy |
| DICE | DICE Therapeutics | $47.55 | $60.00 | 26.18% | Buy |
| CRNX | Crinetics Pharmaceuticals | $56.82 | $70.14 | 23.44% | Buy |
| KRTX | Karuna Therapeutics | $329.83 | $257.50 | -21.93% | Buy |
KALV Forecast FAQ
Is KalVista Pharmaceuticals a good buy?
Yes, according to 4 Wall Street analysts, KalVista Pharmaceuticals (KALV) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 100.00% of KALV's total ratings.
What is KALV's price target?
KalVista Pharmaceuticals (KALV) average price target is $26 with a range of $20 to $38, implying a 123.56% from its last price of $11.63. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will KalVista Pharmaceuticals stock go up soon?
According to Wall Street analysts' prediction for KALV stock, the company can go up by 123.56% (from the last price of $11.63 to the average price target of $26), up by 226.74% based on the highest stock price target, and up by 71.97% based on the lowest stock price target.
Can KalVista Pharmaceuticals stock reach $20?
KALV's average twelve months analyst stock price target of $26 supports the claim that KalVista Pharmaceuticals can reach $20 in the near future.
Did the KALV's actual financial results beat the analysts' financial forecasts?
In terms of the last quarterly report (Jan 2020), KalVista Pharmaceuticals's revenue was $1.58M, missing the average analysts' forecast of $10.08M by -84.35%. The company's EBITDA was $-12.583M, missing the average prediction of $2.02M by -724.30%. KalVista Pharmaceuticals's net income was $-9.291M, missing the average estimation of $-12.087M by -23.13%. The company's SG&A was $3.07M, missing the average forecast of $10.76M by -71.48%. Lastly, the company's EPS was $-0.3, beating the average prediction of $-0.261 by 14.75%